Discrepancies in pharmacokinetic analysis results obtained by using two standard population pharmacokinetics software programs

Fundamental and Clinical Pharmacology

Volumn 23, Issue 1, 2009, Pages 53-57

  Finkelstein, Yaron ^a,b,c   Nava Ocampo, Alejandro A ^a,d,e   Schechter, Tal ^a,b   Grant, M D Ronald ^a,b   Pierre, Edith St ^a   Goldman, Ran ^a,b   Walker, Scott ^a   Koren, Gideon ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e PharmaReasons   (Canada)

Author keywords

Modeling; Population pharmacokinetics; Software

Indexed keywords

DOXORUBICIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CHILD; CLINICAL ARTICLE; COMPUTER PROGRAM; DRUG BLOOD LEVEL; DRUG HALF LIFE; FEMALE; HUMAN; INFANT; MALE; MULTIPLE CYCLE TREATMENT; NEPHROBLASTOMA; NEUROBLASTOMA; POPULATION MODEL; PRESCHOOL CHILD; PRIORITY JOURNAL; RHABDOMYOSARCOMA;

ALGORITHMS; ANTIBIOTICS, ANTINEOPLASTIC; CHILD, PRESCHOOL; DOXORUBICIN; FEMALE; HUMANS; INFANT; MALE; MODELS, BIOLOGICAL; NEOPLASMS; SOFTWARE; TISSUE DISTRIBUTION; VALIDATION STUDIES AS TOPIC;

EID: 61349130074     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2008.00641.x     Document Type: Article

References (10)

1. Kauffman R.E., Kearns G.L. Pharmacokinetic studies in paediatric patients. Clinical and ethical considerations. Clin. Pharmacokinet. (1992) 23 10 29.
2. Meibohm B., Läer S., Panetta J.C., Barrett J.S. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J. (2005) 7 E475 E487.
3. Anderson B.J., Allegaert K., Holford N.H. Population clinical pharmacology of children: modelling covariate effects. Eur. J. Pediatr. (2006) 165 819 829.
4. Rousseau A., Marquet P. Application of pharmacokinetic modelling to the routine therapeutic drug monitoring of anticancer drugs. Fundam. Clin. Pharmacol. (2002) 16 253 262.
5. Li C., Kuti J.L., Nightingale C.H., Nicolau D.P. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J. Clin. Pharmacol. (2006) 46 1171 1178.
6. Wong M., Balleine R.L., Blair E.Y. et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J. Clin. Oncol. (2006) 24 2448 2455.
7. Staatz C.E., Tett S.E. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus. Eur. J. Clin. Pharmacol. (2002) 58 597 605.
8. Callegari T., Caumo A., Cobelli C. Generalization of map estimation in SAAM II: validation against ADAPT II in a glucose model case study. Ann. Biomed. Eng. (2002) 30 961 968.
9. Ummenhofer W.C., Arends R.H., Shen D.D., Bernards C.M. Comparative spinal distribution and clearance kinetics of intrathecally administered morphine, fenatnyl, alfentanil, and sulfentanil. Anesthesiology (2000) 92 739 753.
10. Bauer R.J., Guzy S., Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J. (2007) 9 E60 E83.